Certified Researchers

Structural Heart Devices Market Summary

The Global Structural Heart Devices Market size was valued at USD 0.77 Billion in 2024, and the market is projected to grow from USD 0.821 Billion in 2025 to USD 1.559 Billion by 2035, registering a CAGR of 6.6% during the forecast period 2025–2035. North America led the market with over 38.96% share, generating around USD 0.3 billion in revenue.

The Structural Heart Devices Industry is primarily driven by the increasing prevalence of cardiovascular diseases and rising adoption of minimally invasive cardiac procedures. Advancements in transcatheter technologies, growing geriatric populations, and improved patient outcomes are accelerating demand for innovative structural heart treatment solutions globally across healthcare systems.

According to the World Health Organization, cardiovascular diseases cause approximately 17.9 million deaths annually, representing the leading global cause of mortality. Additionally, the Institute for Health Metrics and Evaluation highlights rising incidence of valvular heart diseases among aging populations, strengthening demand for advanced structural heart intervention devices and minimally invasive procedures.

Key Market Trends & Highlights

The Structural Heart Devices Market is poised for robust growth driven by technological advancements and increasing healthcare needs.

North America dominated the Structural Heart Devices Market in 2024, accounting for over 38.96% of global market revenue.
Europe Structural Heart Devices Market reached USD 0.231 billion in 2024, representing approximately 30% of total global market share.
Cardiovascular diseases cause approximately 17.9 million deaths annually worldwide, significantly increasing demand for structural heart treatment technologies.
Heart disease causes nearly 695,000 deaths annually in the United States, accelerating adoption of minimally invasive cardiac procedures.

Market Size & Forecast

2024 Market Size	0.77 (USD Billion)
2035 Market Size	1.559 (USD Billion)
CAGR (2025 - 2035)	6.62%

Major Players

Companies such as Medtronic (US), Edwards Lifesciences (US), Abbott Laboratories (US), Boston Scientific (US), Cardinal Health (US), LivaNova (GB), Terumo Corporation (JP), JenaValve Technology (DE), AtriCure (US) are some of the major participants in the global market.

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Structural Heart Devices Market Trends

The Global Structural Heart Devices Market is currently experiencing a transformative phase, characterized by rapid advancements in technology and an increasing prevalence of heart diseases. This market encompasses a range of devices designed to treat structural heart conditions, which are often complex and require specialized interventions. The growing awareness of these conditions, coupled with an aging population, appears to be driving demand for innovative solutions. Furthermore, the integration of minimally invasive techniques is reshaping treatment paradigms, offering patients safer and more effective options. These evolving structural heart devices Industry trends are reshaping treatment pathways within the broader structural heart disease treatment devices market. As healthcare systems evolve, the emphasis on patient-centric care is likely to further propel the global market forward.

In addition, the competitive landscape of the global market is becoming increasingly dynamic, with numerous players striving to introduce cutting-edge products within the expanding structural heart occlusion devices market. Collaborations between medical device manufacturers and healthcare providers may enhance the development of novel therapies. Regulatory bodies are also playing a crucial role in ensuring the safety and efficacy of these devices, which could influence structural heart devices market growth. Overall, the global industry seems poised for substantial expansion, driven by technological innovations and a commitment to improving patient outcomes.

Technological Advancements

The Global Structural Heart Devices Market is witnessing a surge in technological innovations, particularly in the development of minimally invasive procedures and advancements emerging from the transcatheter heart valves pipeline product market. These advancements are enhancing the precision and effectiveness of treatments, thereby improving patient recovery times and outcomes. As new materials and techniques emerge, the potential for more effective interventions increases.

According to the World Health Organization, cardiovascular diseases account for nearly 32% of all global deaths, increasing demand for advanced structural heart interventions. Innovations in transcatheter valve replacement systems and minimally invasive technologies are significantly improving procedural precision, patient recovery rates, and long-term cardiovascular treatment outcomes worldwide.

Aging Population

The demographic shift towards an older population is significantly impacting the global market. As age-related heart conditions become more prevalent, the demand for specialized devices is likely to rise. This trend underscores the necessity for healthcare systems to adapt and provide adequate resources for managing these conditions.

The United Nations Population Fund states that the global population aged 65 years and older is increasing rapidly, contributing to higher prevalence of age-related valvular heart disorders. This demographic shift is accelerating demand for minimally invasive structural heart procedures, particularly transcatheter therapies among elderly cardiovascular patients.

Regulatory Developments

Regulatory frameworks surrounding the mrket are evolving, with an emphasis on ensuring patient safety and device efficacy. These developments may influence the pace of innovation and market entry for new products. As regulations become more stringent, manufacturers may need to invest more in compliance and quality assurance.

According to the European Centre for Disease Prevention and Control, strengthening healthcare regulatory systems and medical technology oversight across Europe is supporting safer cardiovascular treatment adoption. Enhanced regulatory frameworks are encouraging innovation, improving device safety standards, and accelerating clinical acceptance of structural heart technologies in major healthcare institutions.

Structural Heart Devices Market Drivers

Growing Awareness and Education

The growing awareness and education regarding cardiovascular health are pivotal in driving the Structural Heart Devices Industry. As patients become more informed about heart diseases and available treatment options, there is a greater demand for effective medical devices. Educational campaigns by healthcare organizations and advocacy groups are instrumental in disseminating information about the risks associated with cardiovascular conditions and the benefits of structural heart devices.

This heightened awareness is likely to lead to increased patient consultations and, consequently, a rise in the adoption of these devices. The global market is expected to expand as more individuals seek proactive measures to manage their heart health.

Increased Healthcare Expenditure

Rising healthcare expenditure across various regions is a significant driver for the Structural Heart Devices Market. As countries allocate more resources to healthcare, there is a corresponding increase in the availability and accessibility of advanced medical technologies. This trend is particularly evident in developed economies, where healthcare budgets are expanding to accommodate innovative treatments for cardiovascular diseases.

The global market for structural heart devices is likely to benefit from this increased investment, as hospitals and clinics seek to adopt cutting-edge technologies to enhance patient care. Furthermore, the growing emphasis on preventive healthcare may lead to earlier interventions, further boosting the demand for these devices.

Regulatory Support and Approvals

Regulatory support and streamlined approval processes for new medical devices are crucial drivers for the Structural Heart Devices Market. Regulatory bodies are increasingly recognizing the need for innovative solutions to address the growing burden of cardiovascular diseases. This has led to expedited review processes for novel devices, facilitating quicker market entry.

As a result, manufacturers are more inclined to invest in research and development, knowing that their products may receive timely approvals. This trend is likely to enhance competition within the global market, leading to a wider array of options for healthcare providers and patients alike. The favorable regulatory environment is expected to contribute to the overall growth of the global industry.

Technological Innovations in Device Design

Technological advancements in the design and functionality of structural heart devices are significantly influencing the global market. Innovations such as minimally invasive procedures, improved imaging techniques, and enhanced biocompatibility are transforming treatment paradigms. These advancements not only improve patient outcomes but also reduce recovery times, making procedures more appealing to both patients and healthcare providers.

The global industry is experiencing a surge in the introduction of novel devices, including transcatheter heart valves and left atrial appendage closure devices. This influx of innovative products is expected to drive market growth, as they offer safer and more effective alternatives to traditional surgical methods.

Rising Prevalence of Cardiovascular Diseases

The increasing incidence of cardiovascular diseases is a primary driver for the Structural Heart Devices Market. As heart conditions such as heart failure, atrial fibrillation, and valvular heart diseases become more prevalent, the demand for innovative treatment solutions rises. According to recent estimates, cardiovascular diseases account for a substantial portion of global mortality, necessitating advanced medical interventions.

This trend is likely to propel the global market for structural heart devices, as healthcare providers seek effective solutions to manage these conditions. The global industry is projected to witness a compound annual growth rate of approximately 8% over the next few years, reflecting the urgent need for these devices in clinical practice.

Market Segment Insights

By Type: Transcatheter Aortic Valve Replacement (Largest) vs. Mitral Valve Repair Devices (Fastest-Growing)

In the Structural Heart Devices Market, the segment values are characterized by varying degrees of market presence and growth potential. Transcatheter Aortic Valve Replacement (TAVR) currently holds a 49% of market share, owing to its wide acceptance in the treatment of aortic stenosis and the increasing demand for minimally invasive procedures. Mitral Valve Repair Devices, while smaller in market share, are rapidly gaining traction due to advancements in repair techniques and greater awareness of mitral valve diseases among healthcare professionals and patients alike. The growth trends in this segment reflect broader patterns in structural heart devices Industry trends. TAVR's established reputation and ongoing technological innovations are poised to sustain its leading position. Meanwhile, the Mitral Valve Repair Devices segment benefits from a surge in clinical applications and favorable reimbursement policies, which contribute to its emergence as the fastest-growing segment. Increasing investment in R&D and a rise in the geriatric population are further driving demand across both categories.

Transcatheter Aortic Valve Replacement (Dominant) vs. Mitral Valve Repair Devices (Emerging)

Transcatheter Aortic Valve Replacement (TAVR) is dominant in the Structural Heart Devices Market due to its effectiveness and minimally invasive nature, designed primarily for patients with aortic stenosis who are at high risk for open-heart surgery. Its established efficacy and safety profile make it the preferred choice among clinicians and patients. On the other hand, Mitral Valve Repair Devices, classified as emerging, present innovative solutions for mitral valve insufficiency, gaining attention for their potential in less invasive procedures. They are currently positioned to capture a growing share of the global industry, driven by advancements in technology and procedural techniques, as well as increasing collaboration among medical device companies for developing comprehensive treatment options. This dynamic environment hints at a promising future for both segments, albeit with differing growth trajectories.

By Procedure Type: Minimally Invasive (Largest) vs. Surgical (Fastest-Growing)

In the Structural Heart Devices Market, the procedure type segment is notably divided into three main categories: Minimally Invasive, Surgical, and Percutaneous. Among these, Minimally Invasive procedures hold the largest market share of 54%, driven by their efficiency and reduced recovery times. Surgical procedures are also significant but are witnessing a growth surge due to advancements in surgical techniques and technologies, making them increasingly favorable for patients requiring comprehensive treatment.

Surgical (Dominant) vs. Percutaneous (Emerging)

In the ongoing evolution of the Structural Heart Devices Market, Surgical procedures are recognized as the dominant method, characterized by their comprehensive and often multifaceted approach to treating heart conditions. Surgeons utilize these techniques to repair or replace defective heart valves, often leading to improved surgical outcomes. Conversely, Percutaneous interventions are emerging as a key player in the global industry , allowing for treatment through minimally invasive approaches. This is appealing due to lower complications and quicker recovery times, positioning it as an attractive alternative for many patients. As technology improves, the appeal of Percutaneous procedures is expected to grow. Overall, both segments underscore a trend toward patient-centric care that prioritizes recovery and outcome efficiency.

By Indication: Aortic Stenosis (Largest) vs. Mitral Regurgitation (Fastest-Growing)

The Structural Heart Devices Market is significantly impacted by varying indications, with Aortic Stenosis leading the segment with 46% market share due to its high prevalence and demand for surgical intervention. This condition is often treated with transcatheter aortic valve replacement (TAVR), making it the most notable segment. Mitral Regurgitation follows closely, showing considerable growth in recent years as advancements in device technology enhance treatment options for patients and improve clinical outcomes. Furthermore, Heart Failure and Pulmonary Valve Stenosis, while important, occupy smaller portions of the market. Heart Failure is a complex multi-dimensional challenge, driving innovation and investment, while Pulmonary Valve Stenosis remains a niche segment with specific treatment needs, yet it shows potential due to emerging therapies.

Aortic Stenosis: Dominant vs. Mitral Regurgitation: Emerging

Aortic Stenosis remains the dominant indication in the Structural Heart Devices Market, attributable to its commonality in older populations and the necessity for effective intervention methods. Technologies such as TAVR have revolutionized treatment approaches and enhanced patient outcomes. Conversely, Mitral Regurgitation is emerging rapidly fueled by a growing elderly population and innovations that address limitations in traditional surgical procedures. As new devices receive approval and clinical evidence mounts, the Mitral Regurgitation market segment is expected to expand, attracting attention from stakeholders keen on enhancing patient care.

By End User: Hospitals (Largest) vs. Cardiology Clinics (Fastest-Growing)

In the Structural Heart Devices Market, hospitals dominate the end-user segment, holding the largest share of 67% due to their comprehensive healthcare services and access to advanced technology. They cater to a wide range of cardiovascular procedures, attracting patients for complex surgeries and interventions. On the other hand, cardiology clinics are emerging rapidly, benefiting from a growing preference for specialized care and the potential for cost-efficient procedures tailored to patients with heart conditions.

Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals are the dominant end users in the Structural Heart Devices Market, equipped with advanced facilities that cater to a myriad of cardiac surgeries and interventions. Their ability to provide comprehensive care, including pre-operative assessments and post-operative monitoring, solidifies their position in the market. Conversely, ambulatory surgical centers are seen as an emerging segment, offering minimally invasive procedures that often result in shorter recovery times and lower costs. Their growing popularity hinges on patient demand for outpatient care, which offers convenience and efficiency without the longer hospital stays. This trend suggests a shift in how heart care is delivered, with an increasing focus on patient-centered services.

Get more detailed insights about Structural Heart Devices Market

Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America leads in the Structural Heart Devices Market size, accounting for over 38.96% of the global revenue in 2024. The United States remains a dominant contributor to the structural heart device market, representing a major portion of technological innovation. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of cardiovascular diseases, and a strong focus on research and development. Regulatory support from agencies like the FDA further catalyzes innovation and adoption of new technologies, enhancing patient outcomes.

The United States is the primary contributor, with key players such as Medtronic, Edwards Lifesciences, and Abbott Laboratories leading the competitive landscape. The presence of established healthcare systems and a high rate of device adoption among healthcare professionals bolster market growth. Additionally, ongoing clinical trials and product launches are expected to sustain momentum in this sector.

According to the Centers for Disease Control and Prevention, heart disease remains the leading cause of death in the United States, causing approximately 695,000 deaths annually. Rising cardiovascular disease burden, combined with strong FDA support and high adoption of minimally invasive cardiac procedures, continues strengthening North America’s structural heart devices market leadership.

Europe : Emerging Regulatory Frameworks

Europe Structural Heart Devices Market size was valued at USD 0.231billion in 2024, making it the second-largest regional market with a 30% share. Key regional contributors include the france market, germany structural heart devices market, italy structural heart devices market, uk structural heart devices market, and spain structural heart devices market, all benefiting from advanced regulatory frameworks and innovation ecosystems. Increasing awareness of cardiovascular diseases and advancements in minimally invasive procedures are key growth drivers.

Countries like Germany and France are at the forefront, supported by favorable reimbursement policies and government initiatives. Germany leads the market, with significant contributions from companies like Edwards Lifesciences and Boston Scientific. The competitive landscape is characterized by a mix of established players and emerging startups, fostering innovation. Collaborative efforts between healthcare providers and manufacturers are enhancing product development, ensuring that the region remains a vital hub for advancements in structural heart devices.

The World Health Organization reports that cardiovascular diseases account for over 42.5% of annual deaths in Europe, significantly increasing demand for advanced structural heart interventions. Favorable reimbursement policies, advanced healthcare infrastructure, and rising awareness regarding transcatheter procedures continue supporting strong regional market expansion.

Asia-Pacific : Rapidly Growing Market Potential

Asia-Pacific is an emerging powerhouse in the structural heart devices market. Rapid expansion is driven by growth across the japan market, china structural heart devices market, South Korea market, and india market, supported by rising healthcare investments and increasing patient awareness.

Countries like Japan and China are leading the charge, with significant investments in healthcare infrastructure and technology adoption. Japan is a key player, with companies like Terumo Corporation and JenaValve Technology making strides in the market. The competitive landscape is evolving, with both local and international players vying for market share. Government initiatives aimed at improving healthcare access and quality are expected to further drive growth in this region, making it a focal point for future developments in structural heart devices.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa represent an untapped market for structural heart devices, holding about 5% of the global market share The Middle East and Africa represent an untapped market for structural heart devices, including expansion opportunities across the gcc structural heart devices market where healthcare modernization initiatives are accelerating adoption.

Countries like South Africa and the UAE are emerging as key players, supported by government initiatives aimed at enhancing healthcare access. South Africa is leading the market, with a growing number of healthcare facilities adopting advanced medical technologies. The competitive landscape is characterized by a mix of local and international companies, including LivaNova and AtriCure. As healthcare systems evolve and regulatory frameworks improve, the region is poised for significant growth in the market.

Structural Heart Devices Market Regional Image

Key Players and Competitive Insights

The Structural Heart Devices Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of cardiovascular diseases. Major players such as Medtronic (US), Edwards Lifesciences (US), and Abbott Laboratories (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Medtronic (US) focuses on innovation through the development of minimally invasive procedures, while Edwards Lifesciences (US) emphasizes its leadership in transcatheter heart valve technologies. Abbott Laboratories (US) is leveraging its extensive portfolio to expand into emerging markets, thereby diversifying its revenue streams.

Collectively, these strategies not only enhance their competitive edge but also contribute to a rapidly evolving market environment. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach appears to be particularly relevant in the context of the market, which is moderately fragmented, with several key players vying for market share. The collective influence of these companies shapes a competitive structure that encourages innovation and responsiveness to market demands, ultimately benefiting healthcare providers and patients alike. In August 2025, Edwards Lifesciences (US) announced the launch of its next-generation transcatheter aortic valve replacement (TAVR) system, which is designed to enhance patient outcomes through improved delivery mechanisms.

This strategic move underscores the company's commitment to innovation and positions it to capture a larger share of the growing TAVR market. The introduction of this advanced system is likely to strengthen Edwards' competitive position, particularly as the demand for less invasive cardiac procedures continues to rise. In September 2025, Abbott Laboratories (US) expanded its partnership with a leading telehealth provider to integrate remote monitoring capabilities into its structural heart devices.

This initiative not only enhances patient engagement but also aligns with the broader trend of digital health integration. By leveraging telehealth solutions, Abbott is poised to improve patient outcomes and streamline post-operative care, thereby reinforcing its market presence in an increasingly digital healthcare landscape. In October 2025, Medtronic (US) announced a strategic collaboration with a prominent AI technology firm to develop predictive analytics tools for its structural heart devices. This partnership aims to harness artificial intelligence to enhance device performance and patient monitoring.

The integration of AI into Medtronic's offerings could potentially revolutionize patient care by providing real-time insights and improving clinical decision-making, thereby solidifying its leadership in the market. As of October 2025, the competitive trends within the market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the need to collaborate to drive innovation and enhance operational efficiencies. Looking ahead, it is anticipated that competitive differentiation will evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver superior patient outcomes.

Key Companies in the Structural Heart Devices Market include

Industry Developments

Recent developments in the Global Structural Heart Devices Market have shown significant advancements with major players driving growth. Innovations within the evolving structural heart disease treatment devices market continue to enhance procedural efficiency and patient outcomes. In September 2023, Medtronic revealed innovative transcatheter heart valve systems aimed at enhancing patient outcomes. AtriCure launched new technologies in July 2023 that support minimally invasive procedures, capturing increased market share. Edwards Lifesciences has also seen growth, particularly with their heart valve technologies that have demonstrated superior patient benefits. In terms of mergers and acquisitions, SentreHEART announced an acquisition of a small device manufacturer in August 2023, extending their portfolio.

In addition, Boston Scientific is actively pursuing partnerships to expand their range of structural heart devices. The market's valuation is expected to reach USD 18 billion by 2025, driven by a growing aging population and rising prevalence of heart diseases. Notable market trends include the increasing adoption of minimally invasive procedures and advancements in technologies, such as digital tools and remote monitoring. The collaborative efforts between industry players, including LivaNova and Abbott Laboratories, are further enhancing innovation in this sector. Overall, the combination of technological advancements and strategic partnerships is propelling the market forward efficiently.

Future Outlook

Structural Heart Devices Market Future Outlook

The Global Structural Heart Devices Market size is projected to reach USD 1.559 Billion by 2035, growing at a CAGR of 6.62%, driven by technological advancements, increasing prevalence of heart diseases, and rising healthcare expenditure.

New opportunities lie in:

Expansion into emerging markets with tailored product offerings. Development of minimally invasive surgical techniques to enhance patient outcomes. Strategic partnerships with healthcare providers for integrated care solutions.

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in cardiovascular innovations.

Market Segmentation

Structural Heart Devices Market Type Outlook

Transcatheter Aortic Valve Replacement
Mitral Valve Repair Devices
Left Atrial Appendage Closure Devices
Transcatheter Pulmonary Valve

Structural Heart Devices Market End User Outlook

Hospitals
Ambulatory Surgical Centers
Cardiology Clinics

Structural Heart Devices Market Indication Outlook

Aortic Stenosis
Mitral Regurgitation
Heart Failure
Pulmonary Valve Stenosis

Structural Heart Devices Market Procedure Type Outlook

Minimally Invasive
Surgical
Percutaneous

Report Scope

MARKET SIZE 2024	0.77(USD Billion)
MARKET SIZE 2025	0.821(USD Billion)
MARKET SIZE 2035	1.559(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	6.62% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Medtronic (US), Edwards Lifesciences (US), Abbott Laboratories (US), Boston Scientific (US), Cardinal Health (US), LivaNova (GB), Terumo Corporation (JP), JenaValve Technology (DE), AtriCure (US)
Segments Covered	Device Type, Procedure Type, Indication, End Users, Regional
Key Market Opportunities	Advancements in minimally invasive procedures enhance growth potential in the market.
Key Market Dynamics	Technological advancements and regulatory changes drive innovation and competition in the market.
Countries Covered	North America, Europe, APAC, South America, MEA

Market Highlights

Structural Heart Devices Companies

FAQs

What is the projected market valuation of the Structural Heart Devices Market by 2035?

The projected market valuation for the market is expected to reach 1.559 USD Billion by 2035.

What was the market valuation of the Structural Heart Devices Market in 2024?

The overall market valuation was 0.77 USD Billion in 2024.

What is the expected CAGR for the Structural Heart Devices Market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 6.62%.

Which companies are considered key players in the Structural Heart Devices Market?

Key players in the market include Medtronic, Edwards Lifesciences, Abbott Laboratories, and Boston Scientific.

What are the main segments of the Structural Heart Devices Market?

The main segments of the market include Type, Procedure Type, Indication, and End User.

How did the Transcatheter Aortic Valve Replacement segment perform in 2024?

In 2024, the Transcatheter Aortic Valve Replacement segment was valued at 0.3085 USD Billion.

What is the projected value of the Mitral Valve Repair Devices segment by 2035?

The Mitral Valve Repair Devices segment is projected to reach 0.3195 USD Billion by 2035.

What is the expected growth for the Left Atrial Appendage Closure Devices segment during the forecast period?

The Left Atrial Appendage Closure Devices segment is expected to grow from 0.0772 USD Billion in 2024 to 0.1615 USD Billion by 2035.

Which end user segment is anticipated to have the highest valuation by 2035?

The Hospitals end user segment is anticipated to have the highest valuation, projected at 0.785 USD Billion by 2035.

What is the expected performance of the Surgical procedure type segment by 2035?

The Surgical procedure type segment is expected to reach a valuation of 0.4825 USD Billion by 2035.

Author

Author

Rahul Gotadki

Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

Certified Researchers

Customize Report

Research Approach

Secondary Research

The secondary research process entailed a thorough examination of regulatory databases, clinical publications, authoritative cardiac care organizations, and peer-reviewed cardiovascular journals.

Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA) Japan, National Medical Products Administration (NMPA) China, American College of Cardiology (ACC), European Society of Cardiology (ESC), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Thoracic Surgeons (STS), European Association for Cardio-Thoracic Surgery (EACTS), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC) Division for Heart Disease and Stroke Prevention, World Health Organization (WHO) Cardiovascular Disease Database, TVT Registry (Transcatheter Valve Therapy Registry), National Cardiovascular Data Registry (NCDR), and national cardiovascular society reports from key markets. These sources were used to collect procedure statistics (TAVR, TMVR, LAA closure volumes), regulatory approval data (PMA and CE mark approvals), clinical safety studies (5-year valve durability data), demographic trends (aging populations with valvular heart disease), and market landscape analysis for transcatheter heart valves, occluders, annuloplasty rings, and structural heart repair technologies.

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. Division Presidents of Structural Heart, VPs of Cardiac Surgery Innovation, regulatory affairs chiefs, and commercial directors from transcatheter valve manufacturers (TAVR/TMVR), occluder device companies, and surgical heart valve OEMs comprised supply-side sources. The demand-side sources included interventional cardiologists, cardiac surgeons (particularly structural heart specialists), cath lab medical directors, electrophysiologists, and procurement leads from academic medical centers, heart valve centers of excellence, community hospitals, and ambulatory surgical centers. Primary research has confirmed the timelines of the product pipeline (next-generation bioprosthetic valves and annuloplasty systems), validated market segmentation across replacement versus repair procedures, and gathered insights on clinical adoption patterns, TAVR center credentialing requirements, pricing strategies, and reimbursement dynamics (CMS coverage decisions, DRG codes).

Primary Respondent Breakdown:

By Designation: C-level Primaries (30%), Director Level (35%), Others (35%)

By Region: North America (40%), Europe (30%), Asia-Pacific (23%), Rest of World (7%)

Market Size Estimation

Revenue mapping and procedure volume analysis were implemented to determine global market valuation. The methodology comprised the following:

The identification of over 40 key manufacturers in North America, Europe, Asia-Pacific, and Latin America who specialize in structural heart repair systems, annuloplasty rings, occluders, and transcatheter valves.

Product mapping encompasses TAVR (transcatheter aortic valve replacement), TMVR (transcatheter mitral valve replacement), surgical cardiac valves, LAA (left atrial appendage) closure devices, ASD/PFO occluders, annuloplasty repair systems, and accessory delivery systems. Examination of annual revenues that are specific to structural heart portfolios (excluding non-cardiac business entities) as reported and modeled

Coverage of manufacturers that account for 75-80% of the global market share in 2024, such as Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, LivaNova, CryoLife, and emerging transcatheter mitral players

Derive segment-specific valuations for valve replacement, repair, and closure devices through extrapolation using bottom-up (procedure volume × ASP by country, stratified by TAVR high-risk vs. low-risk indications, TMVR repair vs. replacement) and top-down (manufacturer revenue validation against reported structural heart division sales) approaches.